Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
View the Latest: Prices
Filter
-
-
Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act
News ReleaseAs the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers.
-
The Public Weighs In On Medicare Drug Negotiations
FeatureThis data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.
-
Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It
News ReleaseMost of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill –…
-
The Sleeper Health Cost Policy
From Drew AltmanIn this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
-
COVID-19 Test Prices and Payment Policy
Issue BriefThis analysis examines list prices for COVID-19 testing at the largest hospitals in every state and finds they range widely from $20 to $850. Federal law now requires private insurers to cover COVID-19 tests at no cost to the patient and provides funding for people without health insurance.
-
Surprise Medical Bills: New Protections for Consumers Take Effect in 2022
Fact SheetThis summarizes key provisions of the No Surprises Act, enacted in December 2020 to address the problem of unexpected medical bills, and issues that could arise during implementation ahead of its Jan. 1, 2022 effective date.
-
Analysis Examines the Implications of Price Transparency for Providers and Patients as New Rules Go into Effect
News ReleaseA new KFF analysis examines how new federal rules on price transparency for health services may affect patient decision-making and market pricing. As of January 1, 2021, the United States Department of Health and Human Services requires that hospitals publish payer-negotiated rates for common services on their websites.
-
Price Transparency and Price Variation in U.S. Health Services
Issue BriefA new Peterson-KFF analysis examines the potential impact of new federal price transparency rules on patient decision-making and market pricing for health services. The brief also includes new analysis of geographic variation in health prices.
-
How Costly Are Common Health Services in the United States?
FeatureA new chart collection examines what we know about the cost of common health services in the U.S. The analysis shows that costs for many common health services have risen more rapidly than inflation; for example, the average cost of hospital admission among large employer plans increased by about $10,000 (68%) between 2008 and 2018.